Infection Biology Unit, German Primate Center, Kellnerweg 4, 37077 Göttingen, Germany; Faculty of Biology and Psychology, Georg-August-University Göttingen, Wilhelmsplatz 1, 37073 Göttingen, Germany.
Infection Biology Unit, German Primate Center, Kellnerweg 4, 37077 Göttingen, Germany.
Cell. 2022 Feb 3;185(3):447-456.e11. doi: 10.1016/j.cell.2021.12.032. Epub 2021 Dec 24.
The rapid spread of the SARS-CoV-2 Omicron variant suggests that the virus might become globally dominant. Further, the high number of mutations in the viral spike protein raised concerns that the virus might evade antibodies induced by infection or vaccination. Here, we report that the Omicron spike was resistant against most therapeutic antibodies but remained susceptible to inhibition by sotrovimab. Similarly, the Omicron spike evaded neutralization by antibodies from convalescent patients or individuals vaccinated with the BioNTech-Pfizer vaccine (BNT162b2) with 12- to 44-fold higher efficiency than the spike of the Delta variant. Neutralization of the Omicron spike by antibodies induced upon heterologous ChAdOx1 (Astra Zeneca-Oxford)/BNT162b2 vaccination or vaccination with three doses of BNT162b2 was more efficient, but the Omicron spike still evaded neutralization more efficiently than the Delta spike. These findings indicate that most therapeutic antibodies will be ineffective against the Omicron variant and that double immunization with BNT162b2 might not adequately protect against severe disease induced by this variant.
奥密克戎变异株的快速传播表明该病毒可能在全球范围内占主导地位。此外，病毒刺突蛋白的大量突变引发了人们的担忧，即该病毒可能逃避由感染或接种疫苗引起的抗体。在这里，我们报告奥密克戎刺突对大多数治疗性抗体具有抗性，但仍然容易受到 sotrovimab 的抑制。同样，奥密克戎刺突逃避了恢复期患者或接种 BioNTech-Pfizer 疫苗（BNT162b2）个体的抗体中和，其效率比 Delta 变体的刺突高 12-44 倍。与 ChAdOx1（阿斯利康/牛津）/BNT162b2 接种或接种三剂 BNT162b2 诱导的针对奥密克戎刺突的抗体的中和作用更有效，但奥密克戎刺突仍比 Delta 刺突更容易逃避中和作用。这些发现表明，大多数治疗性抗体将对奥密克戎变异株无效，并且用 BNT162b2 进行双重免疫接种可能无法充分预防该变异株引起的严重疾病。
